News and Announcements
OncoSil Medical Quarterly Activities & Cash Flow Report June 2016
- Published July 27, 2016 11:38AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
27th July 2016, ASX Announcement
OncoSil Medical Ltd (ASX: OSL) (Oncosil of the Company), a late stage medical devices company focused on localised treatments for patients with pancreatic and liver cancer today released its Appendix 4C – Quarterly Cashflow report for the quarter ended 30 June 2016 (the Quarter). All financial results are in Australian dollars and are unaudited.
Highlights for the Quarter
- Filed IDE Amendment with u.S. FDA
- Further submission to the Notified Body for CE mark applicatiopn responding to all questions
- Michael Warrener, appointed Global Head of Sale and Marketing
- All 30 June 2016 options exercised for cash, with recipts of $0.9m
- Cash outflow form Operations of $2.0m for the Quarter – closing cash balance of $13.4m
To view the full announcement, please click on the button below.